The boss of US pharmaceutical giant Eli Lilly says there is no looking back from Donald Trump's decision to impose sweeping ...

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, ...

GLP-1 receptor agonists, originally introduced in 2006, have undergone significant advancements over the years. David Ricks, ...

Eli Lilly is advancing its diabetes and obesity treatment with an oral drug, orforglipron. In an exclusive interaction, CEO ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Mounjaro is a very big opportunity, given that a significant number of people have diabetes in India, says the CEO ...

LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.

Dr. Jitendra Singh, a renowned endocrinologist himself, emphasized the unique metabolic challenges faced by India due to its ...

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.